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1. Introduction 
Dysregulated epidermal growth factor receptor (HER1/EGFR) is found in about 50% of 
glioblastoma, the most common primary brain tumor (Karpel-Massler et al., 2009). 
Despite recent improvements of the standard of care which currently comprises gross 
total tumor resection, irradiation and concomitant and adjuvant chemotherapy with 
temozolomide, the prognosis of patients with this disease remains dismal. A variety of 
therapeutic strategies was developed in order to improve the clinical outcome of patients 
with glioblastoma. One such approach involves HER1/EGFR-targeted agents among 
which small-molecule tyrosine kinase (TK) inhibitors (e.g., erlotinib) represent the 
clinically most advanced HER1/EGFR-targeted compounds (Halatsch et al., 2006). While 
experimental studies with erlotinib in the setting of glioblastoma showed promising 
results (Lal et al., 2002; Halatsch et al., 2004), clinical translation failed to prove a 
significant benefit (van den Bent et al., 2009). This finding might be partly explained by 
the fact that erlotinib was shown to exert largely variable antiproliferative effects on 
different human glioblastoma cell lines in vitro and in vivo (Halatsch et al., 2004). Based 
on the observation that there is no established correlation between HER1/EGFR baseline 
expression and erlotinib-induced antiproliferative effects, it seems likely that more 
complex genetic constellations form the molecular basis of the erlotinib-sensitive and 
erlotinib-resistant glioblastoma phenotypes. Identification of the molecular pattern 
determining the erlotinib-resistant phenotype may allow the development of a 
therapeutic concept to overcome resistance towards erlotinib using multi-targeting that 
includes those genes that confer resistance. By analyzing a set of erlotinib-sensitive, 
intermediately responsive and erlotinib-resistant glioblastoma cell lines in an expression 
analysis of 244 prospectively selected genes whose products, among others, constitute the 
HER1/EGFR signaling pathway, expression of two genes, FK506-binding protein 14 
(FKBP14) and Ras-related C3 botulinum toxin substrate 1 (RAC1) were identified to 
significantly correlate with the erlotinib-resistant glioblastoma phenotype (Halatsch et al., 
2008). Thus, interference with these genes may enhance the antiproliferative efficacy of 
erlotinib against glioblastoma.  
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2. HER1/EGFR-targeted therapy in glioblastoma 
2.1 HER1/EGFR – a promising target 
HER1/EGFR plays an important role in the regulation of diverse cellular functions such as 
proliferation or differentiation (Wells, 1999). It belongs to the HER family of receptors and 
contains an extracellular ligand-binding site, a transmembraneous portion and an 
intracellular tyrosine kinase (TK) domain. Activation of HER1/EGFR is triggered by 
binding of e.g. epidermal growth factor (EGF) or transforming growth factor- (TGF-) to 
the ligand-binding site. As a consequence, autophosphorylation of specific tyrosine residues 
within the cytoplasmic catalytic kinase domain of the receptor takes place, initiating further 
downward signaling via the ras-raf-mitogen-activated protein kinase (MAPK) or the 
phosphatidylinositol 3-kinase (PI3-K)/Akt pathways (Arteaga, 2003; Scagliotti et al., 2004).  
Dysregulation of HER1/EGFR was shown to be associated with a variety of neoplastic 
disorders including glioblastoma (Earp et al., 2003). This finding can be explained by the fact 
that aberrant alteration of downstream signal transduction results in a shift of the cellular 
homeostasis towards increased proliferation, tumorigenesis, angiogenesis or invasion 
and/or inhibition of apoptosis, thus towards a neoplastic cellular phenotype (Halatsch et al., 
2006). Gene amplification represents one of the mechanisms that lead to dysregulation of 
HER1/EGFR-mediated signaling and HER1/EGFR overexpression as shown for 40-50% of 
glioblastoma (Salomon et al., 1995). Mutational changes of the intrinsic receptor structure 
constitute another mechanism that may result in uncontrolled HER1/EGFR signaling. The 
most frequent mutant form of HER1/EGFR, termed EGFR variant III (EGFRvIII), results 
from an in-frame deletion of 801 base pairs in the DNA sequence encoding the extracellular 
ligand-binding domain of HER1/EGFR. This truncated receptor variant constitutes 
approximately 60% of all mutants and is characterized by continuous activation 
independent of ligand-binding (Frederick et al., 2000; Karpel-Massler et al., 2010). 
2.2 HER1/EGFR-targeted small molecule TK inhibitors – preclinical studies 
The accumulation of evidence for HER1/EGFR to play a pro-oncogenic role in glioblastoma 
led to the development of a multitude of HER1/EGFR-targeted therapeutic strategies such 
as vaccination therapy, HER1/EGFR-targeted antibodies or small-molecule TK inhibitors 
(Karpel-Massler et al., 2009). In glioblastoma, most clinical experience exists with small-
molecule TK inhibitors such as erlotinib. The mode of action of erlotinib is based on binding 
to the intracellular catalytic TK domain of HER1/EGFR in competition with adenosine 
triphosphate, thereby inhibiting autophosphorylation of the receptor and further 
downstream signaling (Halatsch et al., 2006). In preclinical studies, erlotinib was shown to 
exert a variety of interesting antineoplastic effects in the setting of glioblastoma. Griffero et 
al. showed that treatment with erlotinib at a concentration of 5 µM significantly reduced 
cellular viability of six human glioblastoma-derived tumor-initiating cell lines (Griffero et 
al., 2003). This effect was shown to correlate with decreased EGF-induced phosphorylation 
of HER1/EGFR and subsequent inhibition of the MAPK signaling pathway. In a different 
study, Lal et al. showed that exposure of transformed D54-MG glioblastoma cells (D54-
EGFRvIII) to 20 µM of erlotinib resulted in a significant downregulation of certain genes 
encoding pro-invasive proteins and to significantly inhibit the invasiveness of D54-EGFRvIII 
cells (Lal et al., 2002). In addition, Halatsch et al. showed that the extent of erlotinib-
mediated inhibition of anchorage-independent growth of glioblastoma-derived cell lines 
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correlates inversely with the cellular capability to induce HER1/EGFR mRNA, emphasizing 
the important role of HER1/EGFR in the pathogenesis of glioblastoma (Halatsch et al., 
2004). 
2.3 HER1/EGFR-targeted small molecule TK inhibitors – clinical situation 
The promising findings shown by experimental studies led to the conductance of several 
clinical trials examining the effects of erlotinib in the setting of recurrent or newly diagnosed 
glioblastoma. Erlotinib was shown to fit a reasonable safety profile and was generally well 
tolerated as shown by phase I clinical trials (Krishnan et al., 2006; Prados et al., 2006). With 
regard to its clinical efficacy, varying results were derived from early phase clinical trials. In 
a phase II trial, the effects of erlotinib applied at a dose of 150 mg/d on 42 patients with 
recurrent glioblastoma and 43 patients with non-progressive glioblastoma following 
radiotherapy were examined (Raizer et al., 2010). Median overall survival and progression-
free survival for the patients with recurrent glioblastoma were reported as 6 months and 2 
months, respectively. The patients with non-progressive glioblastoma post radiotherapy 
reached a median overall survival of 14 months. Thus, erlotinib had minimal efficacy in 
patients with recurrent glioblastoma and at best slight efficacy in patients with non-
progressive glioblastoma post radiotherapy compared to historical controls. Other 
investigators showed for 48 patients with recurrent glioblastoma who were treated with 
erlotinib a median overall survival and 6-month progression-free survival that exceeded 
historical data of patients receiving standard chemotherapy (Yung et al., 2010). However, 
this study had to be discontinued due to an insufficient number of responses after a planned 
interim analysis. In a randomized controlled phase II clinical trial, it was finally shown for 
patients with recurrent glioblastoma that erlotinib monotherapy was inferior to the 
treatment with temozolomide or BCNU in terms of clinical efficacy (van den Bent et al., 
2009). Only 11.4% of the patients treated with erlotinib were free of progression after 6 
months compared to 24.1% of the patients in the control group. In addition, no significant 
differences in median overall survival were found among the different treatment groups.  
2.4 Erlotinib and standard radio-/chemotherapy 
Several studies were conducted to evaluate whether treatment with erlotinib might provide 
a clinical benefit when combined with conventional radiochemotherapy. In a phase I/II 
trial, 89 patients with newly diagnosed glioblastoma were treated with erlotinib at a dose of 
150 mg/d starting 1 week prior to fractionated radiotherapy (60 Gy total dose) and 
temozolomide at a dose of 75 mg/m2/d (Brown et al., 2008). The treatment with erlotinib 
was continued during radiotherapy and accompanied by up to 6 cycles of temozolomide at 
a dose of 200 mg/m2/d for 5 days every 4 weeks subsequent to the completion of 
radiotherapy. Median overall survival was 15.7 months which, however, was not 
significantly different from that of the radiotherapy plus temozolomide arm from the 
EORTC 26981/22981-NCIC trial (Mirimanoff et al., 2006).  
In a different phase II clinical trial, 65 patients with newly diagnosed glioblastoma or 
gliosarcoma were treated with erlotinib and fractionated radiotherapy with concomitant 
and adjuvant temozolomide (Prados et al., 2009). Median progression-free survival and 
median overall survival were reported as 8.2 months and 19.3 months, respectively, and 
were thus markably prolonged when compared to a combined historical control. In contrast, 
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rather negative results were reported in 27 patients with newly diagnosed glioblastoma that 
were treated with a maximum dose of 150 mg/d erlotinib and radiotherapy (60 Gy in 30 
fractions) with concurrent (75 mg/m2/d for 42 days) and adjuvant (12 four-week cycles 
comprising each 5 days of 150-200 mg/m2/d) temozolomide (Peereboom et al., 2010). Due 
to lack of efficacy and unacceptable toxicity, this trial had to be closed preterm. Median 
overall survival and median progression-free survival were reported as 8.6 months and 2.8 
months, respectively. Progressive disease was found in 22 patients (67%). In addition, 4 
patients (15%) had an adverse event. Notably, three treatment-related deaths occurred. 
Based on these results, a combined treatment with erlotinib, temozolomide and 
radiotherapy appears antagonistic and dangerous.  
2.5 Erlotinib and other agents 
The fact that treatment with erlotinib alone or together with conventional adjuvant therapies 
does not seem to provide a substantial benefit in this disease emphasizes the necessity for a 
change of strategy. Combining HER1/EGFR TK inhibitors with other targeted agents 
represents one such new promising approach.  
Inhibition of downstream key regulators such as mammalian target of rapamycin (mTOR) 
and PI3-K in addition to the treatment with HER1/EGFR TK inhibitors was shown to be 
favorable in preclinical studies. Combined treatment of phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN)-deficient U87 and SF295 glioblastoma cells with erlotinib 
and rapamycin, an mTOR inhibitor, resulted in a significantly increased anti-proliferative 
effect when compared to cells receiving either agent alone (Wang et al., 2006). Similar results 
were reported by a different group (Fan et al., 2007). Moreover, in this study, an even more 
pronounced antiproliferative efficacy was observed when PI3-K was also inhibited by using 
a dual mTOR/PI3-K inhibitor (PI-103) compared to the treatment with erlotinib and either 
additional inhibition of mTOR or PI3-K. In the clinical setting, 22 patients with recurrent 
glioblastoma treated with erlotinib or gefitinib in combination with sirolimus were shown to 
have a 6-month progression-free survival of 25% (Doherty et al., 2006). However, a phase II 
clinical trial evaluating the therapeutic efficacy of a treatment with 150 mg/d (450 mg/d in 
patients on enzyme-inducing anti-epileptic drugs [EIAEDs]) erlotinib and 5 mg/d (10 mg/d 
in patients on EIAEDs) sirolimus in 32 patients with recurrent glioblastoma reported 
negligible anti-tumor activity (Reardon et al., 2010). Complete or partial responses were not 
observed, and median overall survival and median progression-free survival were 33.8 
weeks and 6.9 weeks, respectively. 
Recently, the clinical efficacy of a combination therapy with erlotinib and bevacizumab was 
examined in the setting of recurrent high-grade glioma (Sathornsumetee et al., 2010). 
Twenty-five patients were treated with bevacizumab at a dose of 10 mg/kg i.v. biweekly 
and erlotinib at a dose of 200 mg/d (500 mg/d in patients on EIAEDs). Overall survival and 
median progression-free survival were favorable (42 weeks and 18 weeks, respectively). In 
addition, in nearly half of the patients a radiographic response was observed. However, a 
similar progression-free survival and radiographic response were derived from historical 
data of patients receiving single-agent therapy with bevacizumab. 
Overall, despite promising results reported by some early phase clinical trials, combining 
HER1/EGFR TK inhibitors with other agents has so far been not overly successful in the 
treatment of patients with glioblastoma. Novel targets need to be identified to overcome 
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resistance towards HER1/EGFR TK inhibitors and to substantially enhance the latter’s 
antineoplastic effects by compounds without overlapping toxicity profile. 
3. FKBP14 and RAC1 – two candidate genes for conferring resistance 
towards erlotinib 
The fact that alterations of HER1/EGFR and its pathway are so frequently encountered in 
glioblastoma while erlotinib failed in the clinical setting reflects the complex architecture of 
tumor-driving signaling pathway networks. This phenomenon is highlighted by findings 
derived from an experimental study showing that erlotinib exerts highly variable 
antiproliferative effects on different human glioblastoma cell lines independent of baseline 
HER1/EGFR expression levels (Halatsch et al., 2004). By analyzing HER1/EGFR pathway 
gene expression profiles of glioblastoma cell lines displaying an erlotinib-responsive, 
somewhat responsive and erlotinib-resistant phenotype, FKBP14 and RAC1 were identified 
as candidate genes conferring resistance to erlotinib (Halatsch et al., 2008). This fact may 
render FKBP14 and RAC1 potential therapeutic targets in the vicinity of  the EGFR signaling 
pathway, and interference with FKBP14 and/or RAC1 may allow enhancing the efficacy of 
erlotinib against glioblastoma. RAC1 is an important contributor to cell survival in glioma 
and plays an established role in tumorigenesis as well as in tumor maintenance in this 
setting (Senger et al., 2002). With respect to FKBP14, less is known about its function. 
However, data available so far do indicate a tumor-promoting role for its gene product. 
FKBPs are encoded by a multigene family and exert anti-apoptotic effects. In addition, 
FKBP12, a member of this family was reported to be overexpressed in childhood 
astrocytomas (Khatua et al., 2003). Further studies are warranted to evaluate the potential 
benefit of a combinatorial therapeutic regimen including erlotinib and an inhibitor of RAC1 
and/or FKBP14.   
4. Conclusion 
With respect to the treatment of glioblastoma, erlotinib has so far failed to shape clinical 
practice. A consistant therapeutic benefit could be noted neither when erlotinib was applied 
alone nor when it was administered in combination with standard radio-/chemotherapy. 
Recently, the suspicion was raised that erlotinib might even compromise patients’ safety 
when added to temozolomide and radiotherapy (Peereboom et al., 2010). The discrepancy 
between the promising results erlotinib achieved in experimental studies and its clinical 
failure might be partly explained by insufficient penetration of the blood brain barrier and 
the heterogeneity of tumor cells.  
In addition, another important factor underlying glioblastoma resistance towards erlotinib 
could be simultaneous activation of multiple receptor tyrosine kinases (RTKs) with complex 
converging interactions or other key factors mediating pro-neoplastic signaling. Therefore, 
interception of HER1/EGFR-mediated signaling by erlotinib might be compensated, leading 
to maintenance of the cancerous cellular phenotype. Multiple PI3-K-activating RTKs were 
shown to be simultaneously activated in a variety of different glioma cell lines (Stommel et 
al., 2007). In this study, shut-down of either the hepatocyte growth factor receptor or 
HER1/EGFR alone did not significantly inhibit downstream signaling, while the inhibition 
of both markedly decreased PI3-K activation and cell survival. 
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In concordance with this notion, two molecular determinants, RAC1 and FKBP14, are 
overexpressed in glioblastoma cell lines with erlotinib-resistant phenotype, thus 
representing candidate genes for conferring resistance towards erlotinib. Further studies are 
under way examining the potential benefit of a multitargeted therapeutic strategy including 
erlotinib as well as RAC1 and/or FKBP14 inhibitors.  
The current clinical situation of patients with glioblastoma does not allow us to take a rest. 
A continuous search for novel targets and more efficient combination therapies is of 
ultimate urge and requires all our efforts. 
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